|
|
|
|
|
|
Sponsored by: |
Abbott |
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00075231 |
The purpose of this study is to determine whether a simplified lopinavir-ritonavir based therapy will continue to keep the viral load to very low levels after initial treatment with a combination of Kaletra® (lopinavir/ritonavir) plus Combivir® (lamivudine/zidovudine).
Condition | Intervention | Phase |
HIV Infections |
Drug: Kaletra® (lopinavir/ritonavir) Drug: Combivir® (lamivudine, zidovudine) Drug: Sustiva® (efavirenz) |
Phase II |
MedlinePlus related topics: | AIDS |
ChemIDplus related topics: | Zidovudine Lamivudine Efavirenz Ritonavir Lopinavir Combivir |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Open-Label Study Exploring a Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control:
Exclusion Criteria
United States, California | |||||
Fountain Valley Regional Hospital and Medical Center | |||||
Fountain Valley, California, United States, 92708 |
Abbott |
Study Director: | Barbara da Silva, M.D. | Abbott |
Study ID Numbers: | M03-613 |
First Received: | January 6, 2004 |
Last Updated: | September 28, 2006 |
ClinicalTrials.gov Identifier: | NCT00075231 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|